The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: A systematic review and economic evaluation

Health Technology Assessment

Volumn 20, Issue 34, 2016, Pages

  Shepherd, Jonathan ^a   Cooper, Keith ^a   Harris, Petra ^a   Picot, Joanna ^a   Rose, Micah ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; PLACEBO; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; QUALITY OF LIFE; REMISSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT PLANNING; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; TREATMENT OUTCOME;

ABATACEPT; ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; ETANERCEPT; HUMANS; METHOTREXATE; TREATMENT OUTCOME;

EID: 84966676761     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20340     Document Type: Review

References (174)

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49. http://dx.doi.org/10.1016/S0140-6736(11)60244-4
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78. http://dx.doi.org/ 10.1016/S0140-6736(07)60363-8
3. Rigante D, Bosco A, Esposito S. The etiology of juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2015;49:253-61. http://dx.doi.org/10.1007/s12016-014-8460-9
4. Duffy CM, Colbert RA, Laxer RM, Schanberg LE, Bowyer SL. Nomenclature and classification in chronic childhood arthritis: time for a change? Arthritis Rheum 2005;52:382-5. http://dx.doi.org/ 10.1002/art.20815
5. Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J 2010;8:20-8. http://dx.doi.org/10.1186/1546-0096-8-20
6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton,2001. J Rheumatol 2004;31:390-2.
7. Arthritis Research UK. What are the Different Types of JIA? 2014. URL: www.arthritisresearchuk.org/ arthritis-information/conditions/juvenile-idiopathic-arthritis/different-types.aspx (accessed October 2014).
8. Arthritis Care. Arthritis in Children. URL: www.arthritiscare.org.uk/aboutarthritis/conditions/ arthritisinchildren (accessed October 2014).
9. Arthritis Care. My Child has Oligoarticular JIA. A Guide to the Condition and its Treatment. London: Arthritis Care; 2013.
10. Arthritis Care. My Child has Polyarticular JIA. A Guide to the Condition and its Treatment. London: Arthritis Care; 2013.
11. Arthritis Care. My Child has Systemic JIA. A Guide to the Condition and its Treatment. London: Arthritis Care; 2013.
12. National Rheumatoid Arthritis Society. What is JIA? 2014. URL: www.nras.org.uk/information-onjia-what-is-jia-81 (accessed October 2014).
13. McErlane F, Beresford MW, Baildam EM, Thomson W, Hyrich K, Chieng A, et al. Validation of JADAS in all ILAR subtypes of juvenile idiopathic arthritis in the clinical setting (oral presentation). Rheumatology 2012;51:S27-S38. http://dx.doi.org/10.1093/rheumatology/kes119
14. Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010;62:3131-9. http://dx.doi.org/10.1002/art.27670
15. Minden K, Kiessling U, Listing J, Niewerth M, Doring E, Meincke J, et al. Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 2000;27:2256-63.
16. Bertilsson L, Andersson-Gare B, Fasth A, Petersson IF, Forsblad-D’elia H. Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. J Rheumatol 2013;40:715-24. http://dx.doi.org/10.3899/jrheum.120602
17. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 2014;81:112-17. http://dx.doi.org/10.1016/j.jbspin.2013.09.003
18. Parsons S, Ingram M, Clarke-Cornwell SM, Symmons DPM. A Heavy Burden. The Occurrence and Impact of Musculoskeletal Conditions in the United Kingdom Today. Manchester: The University of Manchester and Arthritis Research UK; 2011.
19. Martin K. Juvenile Idiopathic Arthritis (JIA) Explained. 2014. URL: www.ccaa.org.uk/index.php?id=3 (accessed October 2014).
20. NHS England Clinical Reference Group for Paediatric Medicine. Interim Clinical Commissioning Policy Statement: Biologic Therapies for the treatment of Juvenile Idiopathic Arthritis (JIA). 2015. URL: www.engage.england.nhs.uk/consultation/specialised-services-policies/user_uploads/biolgcs-juvenl-idiop-arthrs-pol.pdf (accessed April 2015).
21. Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2013. 2014. URL: www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-322718 (accessed April 2015).
22. Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WE, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 2002;41:1183-9. http://dx.doi.org/10.1093/rheumatology/41.10.1183
23. Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers [published online ahead of print January 4 2016]. Rheumatology 2016.
24. Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology 2013;52:1999-2003. http://dx.doi.org/10.1093/rheumatology/ket256
25. Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int 2014;34:1483-8. http://dx.doi.org/10.1007/s00296-014-3022-2
26. Stagi S, Masi L, Capannini S, Cimaz R, Tonini G, Matucci-Cerinic M, et al. Cross-sectional and longitudinal evaluation of bone mass in children and young adults with juvenile idiopathic arthritis: the role of bone mass determinants in a large cohort of patients. J Rheumatol 2010;37:1935-43. http://dx.doi.org/10.3899/jrheum.091241
27. Heiligenhaus A, Heinz C, Edelsten C, Kotaniemi K, Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013;21:180-91. http://dx.doi.org/10.3109/09273948.2013.791701
28. British Society for Paediatric and Adolescent Rheumatology. Guidelines for Screening for Uveitis in Juvenile Idiopathic Arthritis (JIA). 2006. URL: www.bspar.org.uk/DocStore/FileLibrary/PDFs/BSPAR%20Guidelines%20for%20Eye%20Screening%202006.pdf (accessed April 2015).
29. NHS England Specialised Services Clinical Reference Group for Specialised Ophthalmology. Clinical Commissioning Policy: Adalimumab (Humira) and Infliximab (Remicade) as Anti-TNF Alpha Treatment Options for Paediatric Patients with Severe Refractory Uveitis. NHS England; 2015.
30. Tong A, Jones J, Craig JC, Singh-Grewal D. Children’s experiences of living with juvenile idiopathic arthritis: a thematic synthesis of qualitative studies. Arthritis Care Res 2012;64:1392-404. http://dx.doi.org/10.1002/acr.21695
31. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. http://dx.doi.org/10.1002/ 1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R
32. Prince FHM, Otten MH, van Suijlekom-Smit LWA. Diagnosis and management of juvenile idiopathic arthritis. BMJ 2010;341:c6434. http://dx.doi.org/10.1136/bmj.c6434
33. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66. http://dx.doi.org/10.1002/art.24516
34. McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 2013;72:1983-8. http://dx.doi.org/10.1136/annrheumdis-2012-202031
35. Consolaro A, Negro G, Chiara Gallo M, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res 2014;66:1703-9. http://dx.doi.org/10.1002/acr.22393
36. Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 2014;73:1380-3. http://dx.doi.org/10.1136/annrheumdis-2013-204186
37. Horneff G, Becker I. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score. Rheumatology 2014;53:1229-34. http://dx.doi.org/10.1093/ rheumatology/ket470
38. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol 2012;30:S157-S162.
39. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis, Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
40. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929-36. http://dx.doi.org/10.1002/acr.20497
41. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64.
42. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. New Engl J Med 2000;342:763-9. http://dx.doi.org/10.1056/NEJM200003163421103
43. National Institute for Health and Care Excellence. Guidance on the Use of Etanercept for the Treatment of Juvenile Idiopathic Arthritis. NICE technology appraisal (TA35);2002. URL: www.nice.org.uk/guidance/ta35 (accessed October 2014).
44. National Institute for Health and Care Excellence. Tocilizumab for the Treatment of Systemic Juvenile Idiopathic Arthritis. NICE technology appraisals (TA238);2011. URL: www.nice.org.uk/guidance/ta238 (accessed October 2014).
45. European Medicines Agency. Orencia: EPAR-Product Information. 2016. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000701/human_med_000958.jsp& mid=WC0b01ac058001d124 (accessed October 2014).
46. European Medicines Agency. Humira: EPAR-Product Information.2015. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp &mid=WC0b01ac058001d124 (accessed October 2014).
47. European Medicines Agency. Etanercept: EPAR-Product Information. 2014. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid=WC0b01ac058001d124 (accessed October 2014)
48. European Medicines Agency. Tocilizumab: EPAR-Product Information. 2014. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000955/human_med_001042.jsp&mid=WC0b01ac058001d124 (accessed October 2014).
49. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Dec Making 1993;13:322-39. http://dx.doi.org/10.1177/0272989X9301300409
50. Berard RA, Laxer RM. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2013;13:1623-30. http://dx.doi.org/10.1517/14712598.2013.840580
51. Horizon Scanning Centre. Tocilizumab (RoActemra) for Active Polyarticular Juvenile Idiopathic Artheritis-Second Line.2012. URL: www.hsc.nihr.ac.uk/topics/tocilizumab-roactemra-for-activepolyarticular-juv/ (accessed October 2014).
52. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].2011. URL: www.cochrane-handbook.org (accessed June 2015).
53. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91. http://dx.doi.org/10.1016/S0895-4356(97)00049-8
54. Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLOS One 2010;5:e11054. http://dx.doi.org/10.1371/journal. pone.0011054
55. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D’Amico R, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26). http://dx.doi.org/10.3310/hta9260
56. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23. http://dx.doi.org/ 10.1002/art.20904
57. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91. http://dx.doi.org/10.1016/S0140-6736(08)60998-8
58. Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res 2010;62:1542-51. http://dx.doi.org/10.1002/ acr.20283
59. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802. http://dx.doi.org/10.1002/art.27431
60. Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Perez N, Silva CA, et al. Cumulative long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis: results up to 7 years of follow-up. Arthritis Rheum 2012;64:S717-18.
61. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. New Engl J Med 2008;359:810-20. http://dx.doi.org/10.1056/NEJMoa0706290
62. Lovell DJ, Ruperto N, Jarosova K, Nemcova D, Vargova V, Michels H, et al. The impact of adalimumab on growth in patients with juvenile idiopathic arthritis. Arthritis Rheum 2012;64:S329-30.
63. Ruperto N, Lovell DJ, Jarosova K, Nemcova D, Vargova V, Michels H, et al. PReS-FINAL-2001: the impact of adalimumab on growth in patients with juvenile idiopathic arthritis. Paediatr Rheumatol 2013;11:O2. http://dx.doi.org/10.1186/1546-0096-11-S2-O4
64. Ruperto N, Lovell D, Quartier P, Ravelli A, Karunaratne M, Kalabic J, et al. Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial. Ann Rheum Dis 2014;73:130-1. http://dx.doi.org/10.1136/annrheumdis-2014-eular.1600
65. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26. http://dx.doi.org/10.1002/art.10710
66. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94. http://dx.doi.org/10.1002/art.21885
67. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. http://dx.doi.org/10.1002/art.23427
68. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015;74:1110-17. http://dx.doi.org/10.1136/annrheumdis-2014-205351
69. Brunner H, Ruperto N, Zuber Z, Cuttica RJ, Xavier R, Calvo I, et al. A4: Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: 2-year data from CHERISH. Arthritis Rheumatol 2014;66:S5-S6. http://dx.doi.org/10.1002/art.38415
70. Baildam E, Ramanan A, Woo P, Brunner H, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in polyarticular-course juvenile idiopathic arthritis: 2 year data from cherish. Rheumatology 2014;53:S52-3.
71. Brunner HI, Ruperto N, Zuber Z, Cuttica RJ, Xavier R, Calvo I, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: 2-year data from Cherish. Arthritis Rheum 2013;65:S335.
72. De Benedetti F, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial. Ann Rheum Dis 2013;72:70. http://dx.doi.org/10.1136/annrheumdis-2013-eular.265
73. Baildam E, Ruperto N, Brunner H, Zuber Z, Keane C, Harari O, et al. Efficacy and safety of tocilizumab in polyarticular juvenile idiopathic arthritis: cherish results at week 40. Rheumatology 2013;52:35.
74. De Benedetti F, Ruperto N, Zuber Z, Cuttica R, Xavier R, Calvo I, et al. PReS-FINAL-2180: efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH. Paediatr Rheumatol 2013;11:O15. http://dx.doi.org/10.1186/ 1546-0096-11-S2-O15
75. Brunner H, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial. Arthritis Rheum 2012;64:S682.
76. Bharucha KN, Brunner HI, Ruperto N, Cabral DA, Gedalia A, Gerloni V, et al. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase 3 Clinical Trial. American College of Rheumatology Annual Scientific Meeting, in Boston, MA, 14-19 November 2014.
77. Abbvie. Adalimumab Multiple technology appraisal (MTA): Etanercept, Abatacept, Adalimumab and Tocilizumab for Treating Juvenile Idiopathic Arthritis (including review of TA35). MTA submission; 2015.
78. Roche. Tocilizumab (RoActemra®) for the Treatment of Juvenile Idiopathic Polyarthritis. MTA submission; 2015.
79. Otten MH, Anink J, Spronk S, Van Suijlekom-Smit LWA. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013;72:1806-12. http://dx.doi.org/10.1136/annrheumdis-2012-201991
80. Nikolakopoulou A, Chaimani A, Veroniki AA, Vasiliadis HS, Schmid CH, Salanti G. Characteristics of networks of interventions: a description of a database of 186 published networks. PLOS One 2014;9:e86754. http://dx.doi.org/10.1371/journal.pone.0086754
81. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f2914. http://dx.doi.org/10.1136/bmj.f2914
82. Kearsley-Fleet L, Davies R, Lunt M, Southwood T, Hyrich K. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) [published online ahead of print December 31 2015]. Rheumatology 2015.
83. Geikowski T, Becker I, Horneff G. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology 2014;53:1245-9. http://dx.doi.org/10.1093/ rheumatology/ket490
84. Albarouni M, Becker I, Horneff G. Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2014;12:35. http://dx.doi.org/10.1186/1546-0096-12-35
85. Bristol-Myers Squibb. Bristol-Myers Squibb (BMS) Abatacept Submission for NICE Multiple Technology Appraisal (MTA) ID738: Abatacept, Adalimumab, Etanercept and Tocilizumab for Treating Juvenile Idiopathic Arthritis (including review of TA35). MTA submission; 2015.
86. Lovell D, Ruperto N, Mouy R, Paz E, Rubio-Pérez N, Silva CA, et al. Cumulative long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis: results up to 7 years of follow-up. American College of Rheumatology (ACR) Congress. Arthritis Rheum 2012;64:S1679.
87. Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 2014;15:14. http://dx.doi.org/10.1186/1745-6215-15-14
88. Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Unnebrink K, Anderson JK. A3: efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. Arthritis Rheumatol 2014;66:S4.
89. Burgos-Vargas R, Tse S, Horneff G, Pangan A, Unnebrink K, Anderson J. Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. J Rheumatol 2014;41:1532-3.
90. Burgos-Vargas R, Tse SML, Horneff G, Pangan AL, Unnebrink K, Anderson JK. Efficacy and safety of adalimumab in paediatric patients with enthesitis related arthritis. Rheumatology 2014;53:i51-2.
91. Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Unnebrink K, Anderson JK. Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. Arthritis Rheum 2013;65:S336.
92. Burgos-Vargas R, Tse S, Horneff G, Pangan AL, Unnebrink K, Anderson JK. PReS-FINAL-2179: efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. Pediatr Rheumatol 2013;11:O14. http://dx.doi.org/10.1186/1546-0096-11-S2-O14
93. Tse SM, Burgos-Vargas R, Horneff G, Pangan AL, Kalabic J, Unnebrink K, et al. Discontinuation of concomitant medication for enthesitis-related arthritis during 52 weeks of treatment with adalimumab. Arthritis Rheumatol 2014;66:S113.
94. Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol 2014;33:1433-41. http://dx.doi.org/10.1007/s10067-014-2498-1
95. Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012;31:1713-21. http://dx.doi.org/10.1007/s10067-012-2082-5
96. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014;66:1073-84. http://dx.doi.org/10.1002/acr.22214
97. Pfizer Ltd. Multiple Technology Appraisal (MTA): Etanercept (Enbrel®) for Treating Juvenile Idiopathic Arthritis (including Review of TA35). MTA submission; 2015.
98. Zeng H, Zeng P, Xie Y, Tang Y, Li F. A randomized controlled clinical trial to evaluate the efficacy of recombinant human tumor necrosis factor-a receptor type II fusion protein antibody in juvenile idiopathic arthritis. Allergy Eur J Allergy Clin Immunol 2013;68:11.
99. Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2014;73:1114-22. http://dx.doi.org/10.1136/annrheumdis-2012-203046
100. Ravelli A, Ruperto N, Pederzoli S, Burgos-Vargas R, Kobusinska K, Schmeling H, et al. Assessment of radiographic progression in patients with polyarticular-course juvenile idiopathic arthritis treated with tocilizumab: 2-year data from CHERISH. Arthritis Rheumatol 2014;66:S17-18. http://dx.doi.org/10.1002/art.38422
101. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17. http://dx.doi.org/10.1177/0272989X12458724
102. Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, et al. A randomized, double-blind, placebo-controlled, multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res 2015;67:1503-12. http://dx.doi.org/10.1002/ acr.22657
103. Foeldvari I, Horneff G, Minden K, Trauzeddel R, Kuemmerle-Deschner JB, Tenbrock K, et al. Remission induction by etanercept in enthesitis related arthritis JIA-patients (juvenile undifferentiated spondylarthropathy). Arthritis Rheumatol 2014;66:3536.
104. Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, et al. Long-term Safety and Efficacy of Etanercept in Paediatric Subjects with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. Arthritis and Rheumatism Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, San Diego, CA, 25-30 October 2013.
105. Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013;21:12-20. http://dx.doi.org/10.3109/09273948.2012.723107
106. Garcia-De-Vicuna C, Diaz-Llopis M, Salom D, Bou R, Diaz-Cascajosa J, Cordero-Coma M, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm 2013;2013:560632. http://dx.doi.org/10.1155/2013/560632
107. Diaz-Llopis M, Salom D, Garcia-De-Vicuna C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012;119:1575-81. http://dx.doi.org/10.1016/j.ophtha.2012.02.018
108. Magli A, Forte R, Navarro P, Russo G, Orlando F, Latanza L, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2013;251:1601-6. http://dx.doi.org/10.1007/s00417-013-2275-x
109. Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013;40:74-9. http://dx.doi.org/10.3899/ jrheum.120583
110. Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J 2013;11:16. http://dx.doi.org/10.1186/1546-0096-11-16
111. Haapasaari JE, Kauppi M, Hakala MS, Kautiainen H. Economic evaluation of etanercept therapy in the treatment of re-fractory JIA. Arthritis Rheum 2002;46:S480.
112. Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L. Etanercept in Patients with Juvenile Idiopathic Arthritis: Systematic Review and Economic Evaluation. 2006. URL: http://hecon.uni-corvinus.hu/ download/english/publ/hecon_research_20_eng.pdf (accessed November 2014).
113. Prince FHM, de Bekker-Grob EW, Twilt M, Van Rossum MAJ, Hoppenreijs EPAH, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis. Clin Exp Rheumatol 2011;29:443. http://dx.doi.org/10.1093/rheumatology/keq432
114. Simpson K, Hubert MM, On PV, Cifaldi M, Shaw J. Long-term cost-effectiveness of adalimumab therapy in juvenile idiopathic arthritis: from a Canadian perspective. J Rheumatol 2012;39:1712.
115. Luca N, Burnett H, Ungar W, Beukelman T, Feldman BM, Schwartz G, et al. Cost-effectiveness analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:S501.
116. Luca N, Burnett H, Ungar W, Beukelman T, Feldman B, Schwartz G, et al. Cost-effectiveness analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol 2012;64(Suppl. S):S501.
117. Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A. Tocilizumab in polyarticular juvenile idiopathic arthritis-a cost-utility model for the United Kingdom. Value Health 2013;16:A564. http://dx.doi.org/10.1016/j.jval.2013.08.1496
118. All Wales Medicines Strategy Group. Adalimumab (Humira®). 2013. http://www.awmsg.org/
119. All Wales Medicines Strategy Group. Etanercept (Enbrel®). 2013. http://www.awmsg.org/
120. All Wales Medicines Strategy Group. Abatacept (Orencia®). 2014. http://www.awmsg.org/
121. All Wales Medicines Strategy Group. Tocilizumab (RoActemra®). 2014. http://www.awmsg.org/
122. Canadian Agency for Drugs and Technologies in Health. Tocilizumab (Actemra-Hoffmann-La Roche Limited) New Indication: Polyarticular Juvenile Idiopathic Arthritis. 2014.
123. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6(17). http://dx.doi.org/10.3310/hta6170
124. Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology 2011;50:1131-6.
125. Simpson K, Marlow N, Shaw J, Rudakova A. Pharmacoeconomic issues of adalimumab therapy in juvenile idiopathic arthritis. Pediatr Pharmacol 2012;9:48-52. http://dx.doi.org/10.15690/ pf.v9i4.390
126. Costa V, Ungar WJ, Hancock-Howard RL. The Use of Biologic Response Modifiers in Polyarticularcourse Juvenile Idiopathic Arthritis. 2010. URL: www.sickkids.ca/pdfs/Research/TASK/biologics/33870-biologics-report_JIA.pdf (accessed 6 November 2014).
127. Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res 2011;63:111-19. http://dx.doi.org/10.1002/acr.20337
128. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
129. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
130. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2013.
131. National Institute for Health and Care Excellence. Guidance on the Use of Etanercept for the Treatment of Juvenile Idiopathic Arthritis. 2002. URL: www.nice.org.uk/guidance/ta35 (accessed 19 May 2015).
132. Simpson K, Shaw J. Mapping the Childhood Health Assessment Questionnaire to the Health Utilities Index Mark 2 and Mark 3 in children with juvenile idiopathic arthritis. 19th Annual Conference of the International Society for Quality of Life Research. Quality Life Res 2012;21:A103.2.
133. Yagudina R, Kulikov A, Zinchuk I. PMS25 evaluation of direct costs for the treatment of active juvenile rheumatoid arthritis using biologics. ISPOR 14th annual European congress. Value Health 2011;14:A306. http://dx.doi.org/10.1016/j.jval.2011.08.411
134. Pennington B, Davis S. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results. Value Health 2014;17:762-71. http://dx.doi.org/10.1016/j.jval.2014.11.002
135. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebocontrolled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. http://dx.doi.org/10.1002/art.22838
136. Hendry GJ, Watt GF, Brandon M, Friel L, Turner DE, Lorgelly PK, et al. The effectiveness of a multidisciplinary foot care program for children and adolescents with juvenile idiopathic arthritis: an exploratory trial. J Rehabil Med 2013;45:467-76. http://dx.doi.org/10.2340/16501977-1130
137. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010;69:138-42. http://dx.doi.org/10.1136/ard.2009.111260
138. Monthly Index of Medical Specialties. Presciption Drug Database and Drug Prescribing Guide. 2014. URL: www.mims.co.uk/ (accessed June 2015).
139. Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for the Treatment of Rheumatoid Arthritis not Previously Treated with Disease-modifying Anti-rheumatic Drugs and After the Failure of Conventional Diseasemodifying Anti-rheumatic Drugs Only: Systematic Review and Economic Evaluation. 2013. URL: www.nice.org.uk/guidance/gid-tag313/ documents/rheumatoid-arthritis-adalimumab-etanercept-infliximab-certolizumab-pegolgolimumab-abatacept-and-tocilizumab-review-assessment-report2 (accessed June 2015).
140. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8(11). http://dx.doi.org/10.3310/hta8110
141. Khan KA, Petrou S, Rivero-Arias O, Walters SJ, Boyle SE. Mapping EQ-5D utility scores from the PedsQL generic core scales. Pharmacoeconomics 2014;32:693-706. http://dx.doi.org/10.1007/ s40273-014-0153-y
142. Briggs AH, O’Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84. http://dx.doi.org/10.1002/hec.584
143. Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Econ 2013;22:22-34. http://dx.doi.org/10.1002/hec.1812
144. British Society for Paediatric and Adolescent Rheumatology. Submission to NICE-MTA-Abatacept, Adalimumab, Etanercept and Tocilizumab for the Treatment of Juvenile Idiopathic Arthritis. MTA submission; 2015.
145. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. New York, NY: Oxford University Press; 2006.
146. Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumor necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:552-7. http://dx.doi.org/10.1136/ard.2007.087130
147. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res 2012;64:1349-56. http://dx.doi.org/10.1002/acr.21697
148. Bruns A, Hilario MO, Jennings F, Silva CA, Natour J. Quality of life and impact of the disease on primary caregivers of juvenile idiopathic arthritis patients. Joint Bone Spine 2008;75:149-54. http://dx.doi.org/10.1016/j.jbspin.2007.07.007
149. Paediatric Formulary Committee. British National Formulary for Children (Online). BMJ Group, Pharmaceutical Press and RCPCH Publications;2015. URL: www.medicinescomplete.com (accessed July 2015).
150. Joint Formulary Committee. British National Formulary (Online). 2014. London: BMJ Group and Pharmaceutical Press. URL: www.bnf.org (accessed July 2015).
151. Curtis L. Unit Costs of Health and Social Care 2013. URL: www.pssru.ac.uk/project-pages/unit-costs/2012/ (accessed July 2015).
152. Department of Health. National Schedule of Reference Costs 2013-14 for NHS Trusts and NHS Foundation Trusts. London: Department of Health; 2014.
153. Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatology 2008;47:985-90. http://dx.doi.org/10.1093/rheumatology/ken039
154. Cummins C, Connock M, Fry-Smith A, Burls A. A Rapid Review of New Drug Treatments for Juvenile Idiopathic Arthritis: Etanercept [TA35 assessment report]. NICE; 2001. URL: www.nice.org.uk/guidance/ta35/documents/assessment-report-for-etanercept-for-juvenile-idiopathic-arthritis-2 (accessed June 2015).
155. Riemsma R, Al Maiwenn J, Lhachimi SK, Armstrong N, Misso K, Manning N, et al. Tocilizumab for the Treatment of Systemic Juvenile Idiopathic Arthritis [TA238 ERG report]. NICE; 2011. URL: www.nice.org.uk/guidance/ta238/documents/arthritis-juvenile-idiopathic-systemictocilizumab-appraisal-consultation-evidence-review-group-report2 (accessed June 2015).
156. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A Systematic Review of the Effectiveness of Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis in Adults and an Economic Evaluation of their Cost-effectiveness [TA130 Assessment Report]. NICE; 2005. URL: www.nice.org.uk/guidance/ta130/documents/rheumatoid-arthritis-adalimumabetanercept-and-infliximab-assessment-report2 (accessed June 2015).
157. Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, et al. Certolizumab Pegol (CIMZIA®) for the Treatment of Rheumatoid Arthritis [TA130 ERG Report]. NICE; 2009. URL: www.nice.org.uk/guidance/ta186/documents/evidence-review-group-report2 (accessed June 2015).
158. Malottki K, Barton P, Tsourapas A, Uthman A, Liu Z, Routh K, et al. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor [TA195 Assessment Report]. NICE; 2009. URL: www.nice.org.uk/guidance/ta195/documents/drugs-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-tnf-inhibitorassessment-report2 (accessed June 2015).
159. Lloyd Jones M, Stevenson M, Stevens J, Sutton A. Abatacept for the Treatment of Rheumatoid Arthritis after the Failure of Conventional Disease-Modifying Anti-rheumatic Drugs [TA247 Rapid Review of TA198, ERG Report]. NICE; 2015. URL: www.nice.org.uk/guidance/ta247/documents/rheumatoid-arthritis-abatacept-2nd-line-evidence-review-group-report3 (accessed June 2015).
160. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306:2340-7. http://dx.doi.org/10.1001/jama.2011.1671
161. Baszis K, Garbutt J, Toib D, Mao J, King A, White A, et al. Clinical outcomes after withdrawal of anti-tumour necrosis factor alpha therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum 2011;63:3163-8. http://dx.doi.org/10.1002/art.30502
162. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62. http://dx.doi.org/ 10.1002/art.21389
163. Kuhlthau K, Kahn R, Hill KS, Gnanasekaran S, Ettner SL. The well-being of parental caregivers of children with activity limitations. Matern Child Health J 2010;14:155-63. http://dx.doi.org/ 10.1007/s10995-008-0434-1
164. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27. http://dx.doi.org/10.2165/00019053-200826070-00008
165. Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, et al. Verteporfin photodynamic therapy cohort study: report 2: clinical measures of vision and health-related quality of life. Ophthalmology 2009;116:2463-70. http://dx.doi.org/10.1016/j.ophtha.2009.10.031
166. National Rheumatoid Arthritis Society (NRAS). A Focus on Juvenile Idiopathic Arthritis.2014. URL: www.nras.org.uk/publications/a-focus-on-juvenile-idiopathic-arthritis-report (accessed May 2015).
167. Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum 2013;42:597-618. http://dx.doi.org/10.1016/j.semarthrit.2012.10.006
168. Kemper A, Van Mater H, Coeytaux R, Williams J, Sanders G. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatrics 2012;12:29. http://dx.doi.org/ 10.1186/1471-2431-12-29
169. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012;51:1407-15. http://dx.doi.org/10.1093/rheumatology/kes019
170. Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Rouster-Stevens K, et al. Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA-associated uveitis. Pediatr Rheumatol Online J 2015;13:19. http://dx.doi.org/10.1186/s12969-015-0018-8
171. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. http://dx.doi.org/10.1136/bmj.d5928
172. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 System. Med Care 2002;40:113-28. http://dx.doi.org/10.1097/00005650-200202000-00006
173. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41:1428-35. http://dx.doi.org/10.1093/ rheumatology/41.12.1428
174. Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8:S49-S60. http://dx.doi.org/10.1007/ s10198-007-0088-8